November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was...
Stents Bioresorbable
This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents
November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients...
November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was...
August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the...
There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on...

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. (Pghoto by Dave Fornell)
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom...
A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president,...
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the...
October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics...
Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands...
June 19, 2018 – Amaranth Medical offered new details about its 85-micron Defiance bioresorbable scaffold (BRS)...
May 31, 2018 – Late-breaking...
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling...
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...
November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report...